Prescribing of anti-osteoporotic therapies following the use of proton pump inhibitors in general practice

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 7, 2010, Pages 763-769

  McGowan, B ^a   Bennett, K ^a   Barry, M ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Anti osteoporotic medications; Bisphosphonates; Co prescribing; Prescribing database; Proton pump inhibitors

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PROTON PUMP INHIBITOR; RALOXIFENE; STRONTIUM RANELATE; TIBOLONE; VITAMIN D; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; BONE MINERAL; CONTROLLED STUDY; DATA BASE; DRUG COST; DRUG INFORMATION; FEMALE; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; BONE DENSITY; COHORT ANALYSIS; DOSE RESPONSE; DRUG EFFECTS; FACTUAL DATABASE; IRELAND; MIDDLE AGED; RISK; STATISTICAL MODEL;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DATABASES, FACTUAL; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IRELAND; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; OSTEOPOROSIS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES;

EID: 77955623208     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1972     Document Type: Article

References (51)

1. Jones R. Clinical economics review: gastrointestinal disease in primary care. Aliment Pharmacol Ther 1996; 10(3): 233-239.
2. Health Services Executive. Primary care reimbursement services. Statistical analysis of claims and payments. 2007.
3. McGowan B, Bennett K, Tilson L, Barry M. Cost effective prescribing of proton pump inhibitors (PPI's) in the GMS scheme. Int Med J 2005; 98(3): 78-80.
4. Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 651-668.
5. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. J Am Med Assoc 2004; 292: 1955-1960.
6. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005; 118: 778-781.
7. Graziani G, Badalamenti S, Como G, et al. Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion. Nephron 2002; 91: 474-479.
8. Graziani G, Como G, Badalamenti S, et al. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant 1995; 10: 1376-1380.
9. Feely J, Chan R, McManus J, O'Shea B. The influence of hospital-based prescribers on prescribing in general practice. Pharmacoeconomics 1999; 16(2): 175-181.
10. de Vries F, Souverein PC, Cooper C, Leufkens HG, Van Staa TP. Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands. Calcif Tissue Int 2007; 80(2): 69-75.
11. Dvorak MM, De Joussineau C, Carter DH, et al. Thiazide diuretics directly induce osteoblast differentiation and mineralized nodule formation by interacting with a sodium chloride co-transporter in bone. J Am Soc Nephrol 2007; 18(9): 2509-2516.
12. Schoofs MW, Van der Klift M, Hofman A, et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med 2003; 139(6): 476-482.
13. LaCroix AZ, Wienpahl J, White LR, et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med 1990; 322(5): 286-290.
14. LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000; 133(7): 516-526.
15. Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 2006; 24(3): 581-589.
16. Masunari N, Fujiwara S, Nakata Y, Furukawa K, Kasagi F. Effect of angiotensin converting enzyme inhibitor and benzodiazepine intake on bone loss in older Japanese. Hiroshima J Med Sci 2008; 57(1): 17-25.
17. Lynn H, Kwok T, Wong SY, Woo J, Leung PC. Angiotension converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 2006; 38(4): 584-588.
18. Douglas C, Bauer MD, Greg R, Mundy MD, Sophie A. Use of statins and fracture. Arch Intern Med 2004; 164(2): 146.
19. Sengwee T, Hernandez-Diaz S. Statins and fracture risk. A systemic review. Pharmacoepidemiol Drug Saf 2007; 16: 627-640.
20. Rejnmark L, Vestergaard P, Mosekilde L. Statin but not non-statin lipid-lowering drugs decrease fracture risk: a nation-wide case-control study. Calcif Tissue Int 2006; 79(1): 27-36.
21. Mattson RH, Gidal BE. Fractures, epilepsy and antiepileptic drugs. Epilepsy Behav 2004; 5 (Supplement 2): S36-40.
22. Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj FG. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002; 58(9): 1348-1353.
23. Pack AM, Morrell MJ. Epilepsy and bone health in adults. Epilepsy Behav 2004; (Sipplement 2): S24-S29.
24. Ensrud KE, Blackwell T, Mangione CM, et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003; 163(8) 949-957.
25. Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reiptake inhibitor use by older men. Arch Intern Med 2007; 167(12): 1246-1251.
26. BNF. Drugs affecting bone metabolism. British National Formulary 2006; 386-387.
27. Diem SJ, Blackwell TL, Stone KL, Yaffe K, Haney EM. Use of antidepressants and rates of hip bone loss in older women. The study of osteoporosis fractures. Arch Intern Med 2007; 167: 1240-1245.
28. Blake GM, Fogelman L. Bone densitometry, steroids and osteoporosis. Curr Opin Nephrol Hypertens 2002; 11: 641-647.
29. Committee on Safety of Medicines. Focus on corticosteroids. Current Problems in Pharmacovigilence 1998; 24: 5-10.
30. Leong GM, Center JR, Henderson NK, Eisman JA. Glucocorticoid-induced osteoporosis, In Osteoporosis. Marcus R, Feldman D, Kelsey J (eds). San diego, Calif.; London: Academic Press 2001; 2: 69-93.
31. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112: 325-364.
32. Hougardy DM, Peterson GM, Bleasel MD, Randall CT. Is enough attention being given to the adverse effects of corticosteroid therapy? J Clin Pharm Ther 2000; 25: 227-234.
33. Yeap SS, Hosking DJ. Management of corticosteroid-induced osteoporosis. Rheumatology 2002; 41: 1088-1094.
34. Williams D, Bennett K, Feely J. Prescribing for osteoporosis following the use of inhaled and oral glucocorticoids in general practice. Br J Clin Pharmacol 2004; 58(6): 665-672.
35. American College of Rheumatology Task Force on Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthrit Rheumatol 1996; 39: 1791-1801.
36. American College of Rheumatology ad hoc committee on glucocorticoid- induced osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. 2001 Update. Arthrit Rheumatol 2001; 44: 1496-1503.
37. Eastell R, Reid DM, Compston J, et al. A UK Consensus Group on management of glucorticoid-induced osteoporosis: an update. J Intern Med 1998; 244: 271-292. (Pubitemid 28473991)
38. Van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. Quart J Med 2000; 93: 105-111. (Pubitemid 30098773)
39. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY. Effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441.
40. Vestergaard P, Rejnmark L, Mosekilde L. Influence of hyper-and hypothyroidism and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. Calcif Tissue Int 2005; 77(3): 139-144.
41. Mohammadi B, Haghpanah V, Tavangar SM, Larijani B. Modelling the effect of levothyroxine therapy on bone mass density in postmenopausal women: a different approach leads to new inference. Theor Biol Med Model 2007; 4: 23.
42. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of nonsteroidal anti-inflammatory drugs, acetylsalicyclic acid, and acetaminophen and the effects of rheumatoid arthritis and osteoarthritis. Calcif Tissue Int 2006; 79: 84-94.
43. Vestergaard P. Pain-relief medication and risk of fractures. Curr Drug Saf 2008; 3: 199-203.
44. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. Can Med Assoc J 2008; 179(4): 319-326.
45. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. J Am Med Assoc 2006; 296(296): 2947-2953.
46. National Council on Ageing and Older People in conjunction with the HSE and the Department of Health and Children. Strategy to prevent falls and fractures in Ireland's ageing population. 2008.
47. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-1767.
48. Leslie WD, Tsang JF, Caetano PA. Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab 2007; 92: 77-81.
49. Sheikh MS, Santa Ana CA, Nicar MJ. Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med 1987; 317: 532-536.
50. Mizunashi K, Furukawa Y, Katano K. Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993; 53: 21-25.
51. National Institute for Clinical Excellence (NICE). Guidance on the use of proton pump inhibitors in the treatment of dyspepsia Technology appraisal guidance - No 7. 2000.